KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sarepta Therapeutics (SRPT) Common Equity (2016 - 2025)

Sarepta Therapeutics (SRPT) has 15 years of Common Equity data on record, last reported at $1.3 billion in Q3 2025.

  • For Q3 2025, Common Equity rose 8.11% year-over-year to $1.3 billion; the TTM value through Sep 2025 reached $1.3 billion, up 8.11%, while the annual FY2024 figure was $1.5 billion, 77.78% up from the prior year.
  • Common Equity reached $1.3 billion in Q3 2025 per SRPT's latest filing, down from $1.4 billion in the prior quarter.
  • Across five years, Common Equity topped out at $1.5 billion in Q4 2024 and bottomed at $385.0 million in Q4 2022.
  • Average Common Equity over 5 years is $868.5 million, with a median of $856.9 million recorded in 2022.
  • Peak YoY movement for Common Equity: crashed 58.52% in 2022, then surged 123.23% in 2023.
  • A 5-year view of Common Equity shows it stood at $928.0 million in 2021, then plummeted by 58.52% to $385.0 million in 2022, then surged by 123.23% to $859.3 million in 2023, then soared by 77.78% to $1.5 billion in 2024, then decreased by 13.59% to $1.3 billion in 2025.
  • Per Business Quant database, its latest 3 readings for Common Equity were $1.3 billion in Q3 2025, $1.4 billion in Q2 2025, and $1.1 billion in Q1 2025.